ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.

Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.